Form 4: Inhibikase Therapeutics Executive Granted Stock Options

Christopher Cabell, President & Head of R&D at Inhibikase Therapeutics, received stock options to purchase 1,100,705 shares of common stock.

Summary

• On February 21, 2025, Christopher Cabell, President & Head of R&D at Inhibikase Therapeutics, Inc., was granted stock options.
• The options allow Cabell to purchase 1,100,705 shares of Inhibikase Therapeutics common stock at an exercise price of $2.23 per share.
• The options vest in three equal installments on the second, third, and fourth anniversaries of February 21, 2025, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. However, it also represents potential future dilution for existing shareholders.

Positives

• The granting of stock options to a key executive like the President & Head of R&D can be seen as an incentive to align their interests with the long-term success of the company.

Risks

• The vesting of the options is contingent upon continued service, meaning if the executive leaves the company before the vesting dates, they will forfeit the unvested options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (1,100,705 shares) would need to be compared to grants given to executives at comparable companies (e.g., companies with similar market capitalization and stage of development) to determine if it is within industry norms.
• Companies like BioNTech, Moderna, and Novavax also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• The grant incentivizes the executive to work towards increasing shareholder value.

Key Dates